Delcath Systems Shareholders Approve Key Amendments at Meeting

Delcath Systems ( (DCTH) ) just unveiled an update.

At the annual meeting on May 15, 2025, Delcath Systems‘ stockholders approved amendments to increase the number of shares available under the company’s 2020 Omnibus Equity Incentive Plan and 2021 Employee Stock Purchase Plan. Additionally, stockholders elected Class I directors, ratified the selection of the company’s independent public accounting firm, and approved a non-binding advisory vote on executive compensation, reflecting shareholder support for the company’s strategic initiatives.

The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.

Spark’s Take on DCTH Stock

According to Spark, TipRanks’ AI Analyst, DCTH is a Neutral.

Delcath Systems is showing strong revenue growth and positive operational developments as highlighted in their recent earnings call, which boosts investor confidence. However, significant risks remain due to ongoing profitability challenges and negative cash flow. The technical analysis suggests bullish momentum, though valuation concerns due to the negative P/E ratio and lack of dividends weigh heavily on the stock’s attractiveness. Investors should be cautious and monitor cash flow improvements and strategy execution closely.

To see Spark’s full report on DCTH stock, click here.

More about Delcath Systems

Delcath Systems, Inc. operates in the medical technology industry, focusing on the development and commercialization of therapies for the treatment of primary and metastatic cancers in the liver. The company is known for its proprietary system designed to deliver high-dose chemotherapy to the liver while minimizing systemic exposure.

Average Trading Volume: 457,622

Technical Sentiment Signal: Hold

Current Market Cap: $538.8M

Find detailed analytics on DCTH stock on TipRanks’ Stock Analysis page.